Tag: CA67059R1091

NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups

Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November

Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November

New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model

Medium and high doses improved movement quality in up to 100% of the animals in a dose-dependent manner

Medium and high doses improved movement quality in up to 100% of the animals in a dose-dependent manner

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub (“HTH”) Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies¹, HTH is operated by the Advanced Regenerative Manufacturing Institute (“ARMI”) and its BioFabUSA initiative.

NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation

Company Is also Seeking Shareholder Approval of Amended and Restated Omnibus Plan

Company Is also Seeking Shareholder Approval of Amended and Restated Omnibus Plan

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsCA67059R1091

AIFA 就涉及 HyalRoute Communication Group Limited 的股份收購交易正式作出澄清及反駁

FREELANDER 8 Makes First Public Appearance Ahead of Official Abu Dhabi Launch

Innoscience Secures Final Victory in Patent Lawsuit as China’s Supreme Court Upholds Injunction Against Infineon GaN Products

Tag: CA67059R1091

NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups

New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us